CHEMCD为您找到'64955-19-7'相关结果约73个

4-HYDROXY-6-NITRO-2-NAPHTHALENECARBOXYLIC ACID

4-HYDROXY-6-NITRO-2-NAPHTHALENECARBOXYLIC ACID

CCD:CCD01996902

CAS:64955-19-7

MDL:MFCD13181450

MF / MW:C11 H7 N O5 / 233.178

同义词:4-HYDROXY-6-NITRO-2-NAPHTHALENECARBOXYLIC ACID;2-NAPHTHALENECARBOXYLIC ACID, 4-HYDROXY-6-NITRO-

http://cn.chemcd.com/prodetailCCD01996902.html

(3Β,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)- TRIENE-3,24,25-TRIO

CCD:CCD08293325

CAS:40013-87-4

同义词:24,25-二羟基维生素 D3;(3Β,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)- TRIENE-3,24,25-TRIO

http://cn.chemcd.com/prodetailCCD08293325.html

25-HYDROXYCHOLECALCIFEROL (6,19,19-D3)

25-HYDROXYCHOLECALCIFEROL (6,<span class='lighter'>19</span>,19-D3)

CCD:CCD01268453

CAS:19356-17-3

MDL:MFCD11656128

MF / MW:C27 H41 D3 O2 / 403.661

同义词:骨化二醇;25-HYDROXYCHOLECALCIFEROL (6,19,19-D3);25-HYDROXYVITAMIN D3 (6,19,19-D3);CALCIFEDIOL;25-HYDROXYVITAMIN-D3-[2H3];CALCIFEDIOL/CALCIDIOL, 25-HYDROXYCHOLECALCIFER,DIDROGYL,HIDROFEROL

http://cn.chemcd.com/prodetailCCD01268453.html

19家医药生物公司上榜“2016年最具投资价值的100家企业”

<span class='lighter'>19</span>家医药生物公司上榜“2016年最具投资价值的100家企业”
2016-10-21 2016年10月20日,在第七届中国高成长企业CEO峰会上,第十一届“中国最具投资价值企业50强·风云榜”和“中国最具投资价值企业50强·新芽榜”正式发布。在入选的100家企业中,有19家医药生物公司上榜了。
http://cn.chemcd.com/news/33163.html

19-NOR-4-ANDROSTENE-3,17-DIONE

<span class='lighter'>19</span>-NOR-4-ANDROSTENE-3,17-DIONE

CCD:CCD00093110

CAS:734-32-7;88128-57-8

MDL:MFCD00199005

MF / MW:C18 H24 O2 / 272.386

同义词:19-NOR-4-ANDROSTENE-3,17-DIONE;(+)-19-NORANDROST-4-ENE-3,17-DIONE;4-ESTREN-3,17-DIONE;19-去甲-4-雄烯-3,17-二酮;ESTRENDIONE;19-NOR-4-ANDROSTANE-3BETA,17BETA-DIOL;19-NORANDROST-4-ENE-3,17-DIONE;3,17-DIOXO-19-NORANDROST-4-ENE;19-NOR-4-ANDROSTEN-3,17-DIONE;9-NOR-4-ANDROSTENEDIONE;ESTRENONE;19-NOR-4-ANDROSTENEDIONE;NORANDROSTENEDIONE;19-NORANDROSTENEDIONE;ESTR-4-ENE-3,17-DIONE;19-NORANDROSTENE-3,17-DIONE;D-19-NORANDROST-4-ENE-3,17-DIONE;甲基双酮;RED CLOVER EXT;19-NORANDROSTENDIONE;19-去甲-4-雄烯二酮;4-ESTRENE-3,17-DIONE

http://cn.chemcd.com/prodetailCCD00093110.html

恒瑞升白药19K将重磅上市,国内G-CSF药物市场格局或生变

恒瑞升白药<span class='lighter'>19</span>K将重磅上市,国内G-CSF药物市场格局或生变
2016-02-25 2月20日,恒瑞医药(证券代码:600276 )重磅创新药聚乙二醇化重组人粒细胞刺激因子注射液(HHPG-19K,19K)的注册状态更新为“正在进行三合一审评”,预计不久后即可获得生产批件。
http://cn.chemcd.com/news/24563.html